Cite
Patrinely JR, Johnson R, Lawless AR, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021;7(5):744-748doi: 10.1001/jamaoncol.2021.0051.
Patrinely, J. R., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., Long, G. V., Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., & Johnson, D. B. (2021). Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA oncology, 7(5), 744-748. https://doi.org/10.1001/jamaoncol.2021.0051
Patrinely, J Randall, et al. "Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma." JAMA oncology vol. 7,5 (2021): 744-748. doi: https://doi.org/10.1001/jamaoncol.2021.0051
Patrinely JR, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021 May 01;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. PMID: 33764387; PMCID: PMC7995124.
Copy
Download .nbib